RIG client Akribion Therapeutics has agreed on an exclusive license of the nuclease, G-dase E, for pharmaceutical applications. This means that Akribion are primed to progress their application pipeline and clinical testing of G-dase E, to provide a novel therapeutic and transform the treatment landscape for a number of applications. Read more here.